Valeant: Much More Upside Remains, Despite Messy Quarter

|
About: Bausch Health Companies Inc. (BHC)
by: Warwick Simons
This article is exclusive for subscribers.
Warwick Simons
Quality Firms, Growth Opportunities, at Unreasonably Low Prices
Summary

Valeant Q2 earnings beat market expectations, but fell short of mine.

Salix performance was very strong; B&L solid too.

Dermatology performance was weak and continues to drag on potential recovery.

Valeant still worth $60/share in late 2019, but I am less bullish than previously.

Valeant (VRX) reported Q2 earnings on Tuesday morning. In this article, I review these earnings and update my investment thesis that I had previously outlined here (Part I and Part II).